I agree, should share some thoughts not just the chart. I...

I agree, should share some thoughts not just the chart. I mentioned before in another post I expected the share price to reset back to $<0.30 after the recent bump.

The company has made some great moves so far this year including renegotiating the loan terms and facilities to provide capital for this year, getting Mildura finally up and running with first harvests underway, gaining interest from GSK, starting the stage three trials etc.

However the company has significant debt and is as of last quarter no where near break even point. Which is a massive put off for a lot of investors and means the company will unlikely hold onto share price increases for the moment (especially in current market conditions) However if things keep going well we might see break even in 2023 and significant share price growth as overall confidence in the companies future grows.

DYOR.